David Katzenstein

Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. J Acquir Immune Defic Syndr. 2009; 52 (1): 106-13

Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. Kassaye S, Johnston E, McColgan B, Kantor R, Zijenah L, Katzenstein D. J Acquir Immune Defic Syndr. 2009; 50 (1): 9-18

Lack of evidence for frequent heterosexual transmission of human herpesvirus 8 in Zimbabwe. Campbell TB, Borok M, Ndemera B, Fiorillo S, White IE, Zhang XQ, Machekano RN, Katzenstein D, Gwanzura L. Clin Infect Dis. 2009; 48 (11): 1601-8

CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic. Abraha A, Nankya IL, Gibson R, Demers K, Tebit DM, Johnston E, Katzenstein D, Siddiqui A, Herrera C, Fischetti L, Shattock RJ, Arts EJ. J Virol. 2009; 83 (11): 5592-605

Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance. Bhattacharya D, Katzenstein D, Wong A, Israelski D, Imperial JC, Keeffe EB, Donovan RM. Int J STD AIDS. 2008; 19 (11): 780-1

Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Arch Intern Med. 2008; 168 (17): 1910-8

A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra CM, Kolson D, Weihe J, Remmel R, Katzenstein D, Clifford DB. Neurology. 2007; 69 (13): 1314-21

Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis. Kassaye S, Lee E, Kantor R, Johnston E, Winters M, Zijenah L, Mateta P, Katzenstein D. AIDS Res Hum Retroviruses. 2007; 23 (8): 1055-61

Factors in the delayed HIV presentation of immigrants in Northern California: implications for voluntary counseling and testing programs. Levy V, Prentiss D, Balmas G, Chen S, Israelski D, Katzenstein D, Page-Shafer K. J Immigr Minor Health. 2007; 9 (1): 49-54

More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175. Shulman NS, Kassaye SG, Winters MA, Johnston E, Katzenstein DA. J Infect Dis. 2007; 196 (2): 328-9; author reply 329-30

Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa. Katzenstein D, J Infect Dis. 2006; 194 Suppl 1 S45-50

Of molecules, macaques and global AIDS. Katzenstein DA, AIDS. 2006; 20 (7): 1065-6

HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes. Rhee SY, Kantor R, Katzenstein DA, Camacho R, Morris L, Sirivichayakul S, Jorgensen L, Brigido LF, Schapiro JM, Shafer RW. AIDS. 2006; 20 (5): 643-51

Perceived risks and benefits of HIV testing, and predictors of acceptance of HIV counselling and testing among pregnant women in Zimbabwe. Martin-Herz SP, Shetty AK, Bassett MT, Ley C, Mhazo M, Moyo S, Herz AM, Katzenstein D. Int J STD AIDS. 2006; 17 (12): 835-41

Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. Lee EJ, Kantor R, Zijenah L, Sheldon W, Emel L, Mateta P, Johnston E, Wells J, Shetty AK, Coovadia H, Maldonado Y, Jones SA, Mofenson LM, Contag CH, Bassett M, Katzenstein DA. J Infect Dis. 2005; 192 (7): 1260-4

Signal-boosted qualitative ultrasensitive p24 antigen assay for diagnosis of subtype C HIV-1 infection in infants under the age of 2 years. Zijenah LS, Tobaiwa O, Rusakaniko S, Nathoo KJ, Nhembe M, Matibe P, Katzenstein DA. J Acquir Immune Defic Syndr. 2005; 39 (4): 391-4

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, Cane P, Clarke J, Sirivichayakul S, Soares MA, Snoeck J, Pillay C, Rudich H, Rodrigues R, Holguin A, Ariyoshi K, Bouzas MB, Cahn P, Sugiura W, Soriano V, Brigido LF, Grossman Z, Morris L, Vandamme AM, Tanuri A, Phanuphak P, Weber JN, Pillay D, Harrigan PR, Camacho R, Schapiro JM, Shafer RW. PLoS Med. 2005; 2 (4): e112

Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. Shulman NS, Delgado J, Bosch RJ, Winters MA, Johnston E, Shafer RW, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 2005; 39 (1): 78-81

The feasibility of voluntary counselling and HIV testing for pregnant women using community volunteers in Zimbabwe. Shetty AK, Mhazo M, Moyo S, von Lieven A, Mateta P, Katzenstein DA, Maldonado Y, Hill D, Bassett MT. Int J STD AIDS. 2005; 16 (11): 755-9

Genetic correlates of efavirenz hypersusceptibility. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. AIDS. 2004; 18 (13): 1781-5

Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. Kantor R, Shafer RW, Follansbee S, Taylor J, Shilane D, Hurley L, Nguyen DP, Katzenstein D, Fessel WJ. AIDS. 2004; 18 (11): 1503-11

The longer the better? Four years of durable, initially boosted protease treatment. Katzenstein D, AIDS. 2004; 18 (5): 811-3

Drug resistance in non-subtype B HIV-1. Kantor R, Katzenstein D. J Clin Virol. 2004; 29 (3): 152-9

Genotype, phenotype, and virtual phenotype: who needs what and why? Katzenstein DA, J Int Assoc Physicians AIDS Care (Chic Ill). 2003 Oct-Dec; 2 (4): 140-6

HIV/AIDS care and treatment in sub-Saharan Africa. Kassaye SG, Katzenstein D. AIDS Rev. 2003 Oct-Dec; 5 (4): 195-204

Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. Kantor R, Katzenstein D. AIDS Rev. 2003 Jan-Mar; 5 (1): 25-35

The evaluation of the HIV/AIDS drug access initiatives in Côte d'Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. Katzenstein D, Laga M, Moatti JP. AIDS. 2003; 17 Suppl 3 S1-4

Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. Shetty AK, Coovadia HM, Mirochnick MM, Maldonado Y, Mofenson LM, Eshleman SH, Fleming T, Emel L, George K, Katzenstein DA, Wells J, Maponga CC, Mwatha A, Jones SA, Abdool Karim SS, Bassett MT. J Acquir Immune Defic Syndr. 2003; 34 (5): 482-90

Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients. Winters MA, Bosch RJ, Albrecht MA, Katzenstein DA. J Infect Dis. 2003; 188 (4): 537-40

High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. Johnston ER, Zijenah LS, Mutetwa S, Kantor R, Kittinunvorakoon C, Katzenstein DA. J Virol. 2003; 77 (13): 7682-8

Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA. AIDS. 2003; 17 (6): 821-30

Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe. Machekano R, Bassett M, McFarland W, Katzenstein D. HIV Clin Trials. 2002 Mar-Apr; 3 (2): 148-54

Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients. Shulman NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. J Acquir Immune Defic Syndr. 2002; 31 (2): 121-7

HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, von Lieven A, Israelski D, Katzenstein DA. AIDS Res Hum Retroviruses. 2002; 18 (18): 1407-13

Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. Shulman NS, Machekano RA, Shafer RW, Winters MA, Zolopa AR, Liou SH, Hughes M, Katzenstein DA. J Acquir Immune Defic Syndr. 2001; 27 (4): 377-80

Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, Israelski DM, Hellmann N, Petropoulos C, Whitcomb J. AIDS. 2001; 15 (9): 1125-32

Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection. Katzenstein DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S. AIDS Res Hum Retroviruses. 2001; 17 (3): 203-10

Vertical transmission of HIV in Africa: diagnostic testing and new interventions. Katzenstein D, HIV Clin Trials. 2000 Nov-Dec; 1 (3): 51-7

Virologic and CD4+ cell responses to new nucleoside regimens: switching to stavudine or adding lamivudine after prolonged zidovudine treatment of human immunodeficiency virus infection. ACTG 302 Study Team. AIDS Clinical Trials Group. Katzenstein DA, Hughes M, Albrecht M, Hammer S, Para M, Murphy R, Valdez H, Haubrich R, Liou S. AIDS Res Hum Retroviruses. 2000; 16 (11): 1031-7

HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. Batra M, Tien PC, Shafer RW, Contag CH, Katzenstein DA. AIDS Res Hum Retroviruses. 2000; 16 (10): 973-9

Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. Shulman NS, Zolopa AR, Passaro DJ, Murlidharan U, Israelski DM, Brosgart CL, Miller MD, Van Doren S, Shafer RW, Katzenstein DA. J Acquir Immune Defic Syndr. 2000; 23 (3): 221-6

Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. Min J, Katzenstein DA. AIDS Res Hum Retroviruses. 1999; 15 (1): 51-5

Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, Chuang TK, Hsu P, White CB, Katzenstein DA. AIDS Res Hum Retroviruses. 1999; 15 (1): 65-9

Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. Katzenstein DA, Mbizvo M, Zijenah L, Gittens T, Munjoma M, Hill D, Madzime S, Maldonado Y. J Infect Dis. 1999; 179 (6): 1382-7

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, Merigan TC, Efron B. Ann Intern Med. 1999; 131 (11): 813-21

Delayed-type hypersensitivity to recombinant HIV envelope glycoprotein (rgp160) after immunization with homologous antigen. Katzenstein DA, Kundu S, Spritzler J, Smoller BR, Haszlett P, Valentine F, Merigan TC. J Acquir Immune Defic Syndr. 1999; 22 (4): 341-7

Primary subtype C HIV-1 infection in Harare, Zimbabwe. Tien PC, Chiu T, Latif A, Ray S, Batra M, Contag CH, Zejena L, Mbizvo M, Delwart EL, Mullins JI, Katzenstein DA. J Acquir Immune Defic Syndr Hum Retrovirol. 1999; 20 (2): 147-53

Geographic and demographic differences in the frequency of human cytomegalovirus gB genotypes 1-4 in immunocompromised patients. Zipeto D, Hong C, Gerna G, Zavattoni M, Katzenstein D, Merigan TC, Rasmussen L. AIDS Res Hum Retroviruses. 1998; 14 (6): 533-6

Polymerase chain reaction detection of Haemophilus ducreyi DNA. Roesel DJ, Gwanzura L, Mason PR, Joffe M, Katzenstein DA. Sex Transm Infect. 1998; 74 (1): 63-5

A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, Katzenstein DA, Merigan TC. J Clin Invest. 1998; 102 (10): 1769-75

Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. Kastrissios H, Suárez JR, Katzenstein D, Girard P, Sheiner LB, Blaschke TF. AIDS. 1998; 12 (17): 2295-303

The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. Kastrissios H, Suárez JR, Hammer S, Katzenstein D, Blaschke TF. AIDS. 1998; 12 (17): 2305-11

Human immunodeficiency virus type 1 RNA shedding in the female genital tract. Goulston C, McFarland W, Katzenstein D. J Infect Dis. 1998; 177 (4): 1100-3

HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. Rey D, Hughes M, Pi JT, Winters M, Merigan TC, Katzenstein DA. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17 (3): 203-8

Adherence as a particular issue with protease inhibitors. Katzenstein DA, J Assoc Nurses AIDS Care. 1997; 8 Suppl 10-7

HIV therapeutics: confronting adherence. Katzenstein DA, Lyons C, Molaghan JP, Ungvarski P, Wolfe GS, Williams A. J Assoc Nurses AIDS Care. 1997; 8 Suppl 46-58

Combination therapies for HIV infection and genomic drug resistance. Katzenstein D, Lancet. 1997; 350 (9083): 970-1

Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responses. Kundu SK, Katzenstein D, Valentine FT, Spino C, Efron B, Merigan TC. J Acquir Immune Defic Syndr Hum Retrovirol. 1997; 15 (4): 269-74

Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. Shafer RW, Eisen JA, Merigan TC, Katzenstein DA. J Virol. 1997; 71 (7): 5441-8

Antiretroviral therapy for human immunodeficiency virus infection in 1997. Katzenstein DA, West J Med. 1997; 166 (5): 319-25

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS. N Engl J Med. 1996; 335 (15): 1091-8

Human immunodeficiency virus in plasma and genital secretions during the menstrual cycle. Goulston C, Stevens E, Gallo D, Mullins JI, Hanson CV, Katzenstein D. J Infect Dis. 1996; 174 (4): 858-61

Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. J Infect Dis. 1996; 173 (4): 1005-8

HIV viral load quantification, HIV resistance, and antiretroviral therapy. Katzenstein DA, Holodniy M. AIDS Clin Rev. 1995-1996; 277-303

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC. J Infect Dis. 1995; 172 (1): 70-8

Viral phenotype and genotype as markers in clinical trials. Katzenstein DA, J Acquir Immune Defic Syndr Hum Retrovirol. 1995; 10 Suppl 2 S25-34

Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, Merigan TC. J Infect Dis. 1994; 169 (2): 416-9

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WA, Gupta P, Rasheed S, Coombs R. J Infect Dis. 1994; 169 (4): 722-9

HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC. J Acquir Immune Defic Syndr. 1994; 7 (8): 832-8

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Ann Intern Med. 1994; 121 (4): 263-8

Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. Ramachandran RV, Katzenstein DA, Wood R, Batts DH, Merigan TC. J Infect Dis. 1994; 170 (4): 1009-13

Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. Wood R, Dong H, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 1993; 6 (3): 237-40

Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. Holodniy M, Katzenstein D, Winters M, Montoya J, Shafer R, Kozal M, Ragni M, Merigan TC. J Acquir Immune Defic Syndr. 1993; 6 (4): 366-9

Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. Hamed KA, Winters MA, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1993; 167 (4): 798-802

Peripheral blood mononuclear cell human immunodeficiency virus type 1 proviral DNA quantification by polymerase chain reaction: relationship to immunodeficiency and drug effect. Montoya JG, Wood R, Katzenstein D, Holodny M, Merigan TC. J Clin Microbiol. 1993; 31 (10): 2692-6

Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. Winters MA, Tan LB, Katzenstein DA, Merigan TC. J Clin Microbiol. 1993; 31 (11): 2960-6

Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. Shafer RW, Kozal MJ, Katzenstein DA, Lipil WH, Johnstone IF, Merigan TC. J Virol Methods. 1993; 41 (3): 297-310

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Merigan TC. J Infect Dis. 1993; 167 (3): 526-32

Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine. Kundu SK, Katzenstein D, Moses LE, Merigan TC. Proc Natl Acad Sci U S A. 1992; 89 (23): 11204-8

Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. Winters MA, Holodniy M, Katzenstein DA, Merigan TC. PCR Methods Appl. 1992; 1 (4): 257-62

Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. Clark AG, Holodniy M, Schwartz DH, Katzenstein DA, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (1): 52-9

Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. Katzenstein DA, Holodniy M, Israelski DM, Sengupta S, Mole LA, Bubp JL, Merigan TC. J Acquir Immune Defic Syndr. 1992; 5 (2): 107-12

Quantitative virological measures of antiretroviral therapy. Katzenstein DA, Holodniy M. AIDS Clin Rev. 1992; 41-67

Relation of the pathogenesis of human immunodeficiency virus infection to various strategies for its control. Merigan TC, Katzenstein DA. Rev Infect Dis. 1991 Mar-Apr; 13 (2): 292-302

Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. Holodniy M, Katzenstein DA, Israelski DM, Merigan TC. J Clin Invest. 1991; 88 (5): 1755-9

Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC. J Infect Dis. 1991; 164 (4): 769-72

Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, Konrad M, Groves E, Merigan TC. J Infect Dis. 1991; 163 (4): 862-6

Inhibition of human immunodeficiency virus gene amplification by heparin. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. J Clin Microbiol. 1991; 29 (4): 676-9

Key Documents

Contact Information

Honors and Awards

Postdoctoral Advisees

Web Site Links

Research Interests

Clinical Trials

Publications